Sacituzumab Tirumotecan Approval in China By Delhi, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The recent approval of sacituzumab tirumotecan in China represents a significant advancement in oncology, particularly in the realm of targeted therapies....

SKB264 Innovative Cancer Antibody Drug Conjugate Clinical Trials Efficacy Insight Delhi, Sept. 19, 2024 (GLOBE NEWSWIRE) -- SKB264, also known as MK-2870, is an innovative antibody-drug conjugate (ADC) targeting TROP2, currently being developed by Kelun Biotech in partnership...